{
    "Project Title": "An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",
    "Sponsor": "Astellas Pharma Global Development Inc. (APGD)",
    "Study Number": "7465-CL-0301",
    "Protocol Version and Date": "Version 4.0, 14 Sep 2020",
    "Study Title": "An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",
    "Phase": "Phase 3",
    "Therapeutic Area": "Urothelial Cancer",
    "Number of Patients": "600 (approximately)",
    "Number of Sites": "Not Available",
    "Indication": "Locally advanced or metastatic urothelial cancer",
    "Duration of Treatment": "28-day cycle for Arm A and 21-day cycle for Arm B",
    "Schedule of Assessments": "Table 1, Section V",
    "questionnaires": [
        {
            "longName": "EORTC Quality of Life Questionnaire",
            "shortName": "QLQ-C30",
            "type": "PRO",
            "questionnaireSchedule": "Baseline (Day -7 to -1), Day 1 of each week for first 12 weeks, then every 12 weeks, EOT and follow-up visit",
            "questionnaireTiming": [
                "Base Date   (Visit  ): Day 1   (Every Cycle  )",
                "Base Date   (Visit  ): Date of Last Dose   (End of Treatment1  )",
                "Base Date   (Visit  ): Date of last Dose + 30 days   (Follow-up2  )"
            ]
        },
        {
            "longName": "EuroQOL 5-dimensions",
            "shortName": "EQ-5D-5L",
            "type": "PRO",
            "questionnaireSchedule": "Baseline (Day -7 to -1), Day 1 of each week for first 12 weeks, then every 12 weeks, EOT and follow-up visit",
            "questionnaireTiming": [
                "Base Date   (Visit  ): Day 1   (Every Cycle  )",
                "Base Date   (Visit  ): Date of Last Dose   (End of Treatment1  )",
                "Base Date   (Visit  ): Date of last Dose + 30 days   (Follow-up2  )"
            ]
        },
        {
            "longName": "Healthcare Resource Utilization Questionnaire",
            "shortName": "HRU",
            "type": "PRO",
            "questionnaireSchedule": "Monthly (Day 1 of every 4 weeks), starting on Week 5, at EOT and follow-up visit",
            "questionnaireTiming": [
                "Base Date   (Visit  ): Day 1   (Every Cycle  )",
                "Base Date   (Visit  ): Date of Last Dose   (End of Treatment1  )",
                "Base Date   (Visit  ): Date of last Dose + 30 days   (Follow-up2  )",
                "Base Date   (Visit  ): Date of Last Dose   (End of Treatment21  )",
                "Base Date   (Visit  ): Date of last Dose +30 days   (Follow-up18  )"
            ]
        }
    ]
}